Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman.
Journal
Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
07
2019
revised:
23
09
2019
accepted:
07
02
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
2
4
2020
Statut:
epublish
Résumé
Acute leukemia during pregnancy is rare (1 for 100000 pregnancies). The association of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is known as the best therapy in standard-risk acute promyelocytic leukemia (APL). We describe the first case of a pregnancy with ATRA and ATO reported in the literature. In March 2018 at the University Hospital of Besançon, a 22-year-old woman was diagnosed with APL at 14 weeks of gestation (WG). She received a total of 2160 mg of ATRA and 930 mg of ATO between 14 and 35 WG. The mother's cytological remission was very fast. No maternal or fetal complications occurred during pregnancy. The pediatrics outcomes were good. Many case reports about ATRA exposure during the second and third trimesters report no serious adverse effect for pregnancy. ATO is teratogenic, genotoxic, and carcinogenic and passes through the placenta. Fetal exposure seems to be associated with bad pregnancy outcomes (preterm delivery, decreased birth weight, and fetal loss) and with lung diseases in young adults. No clinical trial is obviously possible, and the only data available are environmental exposure or animal studies. This case report may help medical teams to make hard decision for a treatment of APL during pregnancy.
Identifiants
pubmed: 32231816
doi: 10.1155/2020/3686584
pmc: PMC7086430
doi:
Types de publication
Case Reports
Langues
eng
Pagination
3686584Informations de copyright
Copyright © 2020 Claire Cochet et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Lancet Child Adolesc Health. 2017 Dec;1(4):302-310
pubmed: 30169185
J Clin Oncol. 2017 Feb 20;35(6):605-612
pubmed: 27400939
Carcinogenesis. 2004 Jan;25(1):133-41
pubmed: 14514661
Blood. 2009 Feb 26;113(9):1875-91
pubmed: 18812465
Hematol Oncol Clin North Am. 2011 Apr;25(2):277-91, vii
pubmed: 21444030
Pharmacotherapy. 2009 Jun;29(6):709-24
pubmed: 19476422
Haematologica. 2018 Dec;103(12):2033-2039
pubmed: 30026341
Lancet Oncol. 2015 Oct;16(13):1295-305
pubmed: 26384238
J Occup Environ Med. 2007 Oct;49(10):1097-104
pubmed: 18000415
Cancer. 2005 Jul 1;104(1):110-7
pubmed: 15912518
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Blood. 2019 Apr 11;133(15):1630-1643
pubmed: 30803991
Environ Res. 2003 Jan;91(1):29-34
pubmed: 12550085
Hematology. 2007 Oct;12(5):415-8
pubmed: 17852449
Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):204-11
pubmed: 18226075
Leukemia. 1997 Mar;11(3):454-5
pubmed: 9067591
Case Rep Hematol. 2015;2015:634252
pubmed: 25821608
Sci Prog. 1999;82 ( Pt 1):69-88
pubmed: 10445007